UC Investments
VC Fund
UC Investments is a VC fund focused on Health Care and Biotechnology. UC Investments
- Total investments:
- 16
- Last investment:
- Lead investor:
- 19%
Last updated:
For AI agents: llms.txt
Industries UC Investments invests in
Health CareBiotechnologyArtificial IntelligenceMachine LearningMedical
Stages UC Investments invests in
Series ASeries BSeedSeries DSeries E
Countries UC Investments invests in
United StatesCanada
Investment Focus
Industry
- Health Care 5 (31%)
- Biotechnology 5 (31%)
- Artificial Intelligence 4 (25%)
- Machine Learning 3 (19%)
- Medical 2 (13%)
Stage
- Series A 4 (25%)
- Series B 4 (25%)
- Seed 2 (13%)
- Series D 1 (6%)
- Series E 1 (6%)
Country
- United States 10 (63%)
- Canada 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Qolab
|
Qolab mission is to build high quality qubits by leveraging the most advanced semiconductor manufacturing processes. | $54.2M / Series B / Jul 02, 2026 | |
Qubic Technologies
|
Qubic Technologies is a manufacturer of quantum microwave transmitters and receivers for remote sensing and communication. | $2.5M / Seed / Jun 23, 2026 | |
Prenosis
|
Prenosis Inc. is a health tech innovator devoted to ushering in a new era of precision diagnostics in acute care using artificial intelligence. Its ImmunixTM precision diagnostics platform leverages machine learning algorithms trained on deep biological data and broad clinical data to more holistically capture and illuminate the complex healthstates of patients. Its proprietary NOSISTM dataset is the largest and fastest growing hybrid biomarker-clinical dataset for sepsis care. The Sepsis ImmunoScoreTM diagnostic on the ImmunixTM platform has the potential to save thousands of lives and billions of dollars in healthcare spending annually. | $20M / Series A / Jan 29, 2026 | |
Arena
|
LM Arena provides a platform for testing AI models. LM Arena serves as an essential resource for researchers and developers worldwide. As the AI field expands, the importance of reliable benchmarking tools like LM Arena remains undeniable. The company also operates Chatbot Arena, a specialized service for evaluating artificial intelligence systems. | $150M / Series A / Jan 06, 2026 | |
|
Arena
|
LM Arena provides a platform for testing AI models. LM Arena serves as an essential resource for researchers and developers worldwide. As the AI field expands, the importance of reliable benchmarking tools like LM Arena remains undeniable. The company also operates Chatbot Arena, a specialized service for evaluating artificial intelligence systems. | $100M / Seed / May 21, 2025 | |
Neurona Therapeutics
|
Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M / Apr 03, 2025 | |
|
Neurona Therapeutics
|
Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M / Series F / Apr 03, 2025 | |
Eikon Therapeutics
|
Eikon Therapeutics is a biopharmaceutical company that focuses on developing innovative technologies for drug discovery. The company utilizes advanced live-cell resolution microscopy and engineering to identify and create new therapeutic candidates. Eikon Therapeutics aims to enhance the understanding of biological processes at a cellular level,supporting targeted treatment development. The company’s approach integrates biology, engineering, and chemistry to streamline the drug discovery process. Through its proprietary platforms, Eikon Therapeutics seeks to advance clinical programs and expand its pipeline of potential medications. | $350.7M / Series D / Feb 26, 2025 | |
Horizon Surgical Systems
|
Horizon Surgical Systems specializes in the development of innovative technologies for microsurgery, focusing on robotics, medical imaging, and artificial intelligence. The company is dedicated to transforming the field of surgical ophthalmology by creating a novel, AI-driven, and imaging-guided surgical robotic system. This initiative aims toenhance the precision and effectiveness of microsurgical procedures, thereby improving patient outcomes. Horizon Surgical Systems is actively engaged in research and development to push the boundaries of what is possible in microsurgery, leveraging the latest advancements in technology to meet the evolving needs of healthcare professionals and patients. | $30M / Series A / Oct 16, 2024 | |
Digestiva
|
Digestiva develops the nutritional, sensory, and physiological properties of food and feed proteins with targeted biocatalysts. | $18.4M / Series A / Jul 15, 2024 | |
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Health Care Investors
43,014 investors
Artificial intelligence Investors
40,702 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Machine Learning Investors
17,935 investors
SaaS VC Funds
61,208 investors
Health Care VC Funds
32,370 investors
FAQ
What does UC Investments invest in?
UC Investments invests primarily in Health Care, Biotechnology and Artificial Intelligence startups, most often at Series A and Series B stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did UC Investments last invest?
The most recent investment recorded for UC Investments closed in Jul 2026. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
